Version 1
: Received: 29 April 2020 / Approved: 30 April 2020 / Online: 30 April 2020 (09:24:37 CEST)
Version 2
: Received: 1 June 2020 / Approved: 3 June 2020 / Online: 3 June 2020 (05:29:09 CEST)
Taguchi, Y.; Turki, T. A New Advanced in Silico Drug Discovery Method for Novel Coronavirus (SARS-CoV-2) with Tensor Decomposition-Based Unsupervised Feature Extraction. PLOS ONE, 2020, 15, e0238907. https://doi.org/10.1371/journal.pone.0238907.
Taguchi, Y.; Turki, T. A New Advanced in Silico Drug Discovery Method for Novel Coronavirus (SARS-CoV-2) with Tensor Decomposition-Based Unsupervised Feature Extraction. PLOS ONE, 2020, 15, e0238907. https://doi.org/10.1371/journal.pone.0238907.
Taguchi, Y.; Turki, T. A New Advanced in Silico Drug Discovery Method for Novel Coronavirus (SARS-CoV-2) with Tensor Decomposition-Based Unsupervised Feature Extraction. PLOS ONE, 2020, 15, e0238907. https://doi.org/10.1371/journal.pone.0238907.
Taguchi, Y.; Turki, T. A New Advanced in Silico Drug Discovery Method for Novel Coronavirus (SARS-CoV-2) with Tensor Decomposition-Based Unsupervised Feature Extraction. PLOS ONE, 2020, 15, e0238907. https://doi.org/10.1371/journal.pone.0238907.
Abstract
Background: COVID-19 is a critical pandemic that has affected human communities worldwide, and there is an urgent need to develop effective drugs. Although there are a large number of candidate drug compounds that may be useful for treating COVID-19, the evaluation of these drugs is time-consuming and costly. Thus, screening to identify potentially effective drugs prior to experimental validation is necessary. Method: In this study, we applied the recently proposed method tensor decomposition (TD)-based unsupervised feature extraction (FE) to gene expression profiles of multiple lung cancer cell lines infected with severe acute respiratory syndrome coronavirus 2. We identified drug candidate compounds that significantly altered the expression of the 163 genes selected by TD-based unsupervised FE. Results: Numerous drugs were successfully screened, including many known antiviral drug compounds such as C646, chelerythrine chloride, canertinib, BX-795, sorafenib, sorafenib, QL-X-138, radicicol, A-443654, CGP-60474, alvocidib, mitoxantrone, QL-XII-47, geldanamycin, fluticasone, atorvastatin, quercetin, motexafin gadolinium, trovafloxacin, doxycycline, meloxicam, gentamicin, and dibromochloromethane. The screen also identified ivermectin, which was first identified as an anti-parasite drug and recently the drug was included in clinical trials for SARS-CoV-2. Conclusions: The drugs screened using our strategy may be effective candidates for treating patients with COVID-19.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
3 June 2020
Commenter:
Y-H. Taguchi
Commenter's Conflict of Interests:
Author
Comment:
Adress concerns raised by reviewers. Mainly addtion of comparisons with two srudies that target directly SARS-CoV-2. In the prebious version, there are no direct comaprisons with other studied that targete SARS-CoV-2 directly.
Commenter: Y-H. Taguchi
Commenter's Conflict of Interests: Author